Clinical trial
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
NCT01412034 is registered in ClinicalTrials.gov with Cerenis Therapeutics, SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
- Lead sponsor
- Cerenis Therapeutics, SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- August 31, 2014
- Enrollment
- 23 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.